Jump to content

Siva Teja Devarakonda

Education:

Saint Louis University
Hometown:  St. Louis, MO
PhD Advisor: Fadi Salloum, PhD, F.A.H.A.
Graduate Program: Physiology and Biophysics

 

Research Interests:

Teja’s undergraduate research experience is in the field of vascular biomechanics. He studied the effect of anti-hypertensive medications (Losartan, hydralazine) on the RNA expression profiles of rat carotid arteries in a bioreactor setting, and utilized computational models in predicting the mechanical properties of mice aorta and carotids.

Currently, Teja works in a molecular cardiology lab focusing on myocardial infarction and heart failure. His work focuses on the cardioprotective properties of the hormone Relaxin, and on understanding the signaling events propagated by RXFP1 - the Relaxin receptor - downstream of activation in the ischemic myocardium. He is also studying ML290, the small molecule agonist of the receptor, to elucidate potentially beneficial pathways and characterize agonist induced biased signaling at RXFP1.

Personal Bio:

Teja was born in the city of Warangal, India and moved to the United States when he was 15 years old. He performed with an Indian fusion A cappella music in college, and plays classical guitar to relax.  He enjoys being outdoors (hiking, running), and harmonizing to random pop hits on the radio. He also likes reading novels for pleasure, and takes his Game of Thrones allegiances seriously.

Publications:

Valle Raleigh J, Mauro AG, Devarakonda T, et al. Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism. Cardiovasc Res. 2017;2:cvw246. doi:10.1093/cvr/cvw246.

Abstracts, Posters, and Presentations:

Cain CK, Devarakonda T, Thompson J, et al. Selective Relaxin Receptor 1 Agonist (ML290) Attentuates Myocardial Ischemic Injury through Preservation of Mitochondrial Function.; 2016.